Author:
Zhang Li,Wang Zhehai,Fang Jian,Yu Qitao,Han Baohui,Cang Shundong,Chen Gongyan,Mei Xiaodong,Yang Zhixiong,Stefaniak Victoria,Lin Yong,Wang Shuyan,Zhang Wen,Sun Luyao,Yang Yunpeng
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference13 articles.
1. Ettinger DS, Wood DE, Aisner DL, et al: NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.202J Natl Compr Canc Netw 19:254-266, 2021.
2. Neoadjuvant immunotherapy for resectable non-small cell lung cancer;Xie;Am J Cancer Res,2021
3. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit;Wang;MAbs,2019
4. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous nsclc: a randomized, double-blind, phase 3 study (oncology pRogram by InnovENT anti-PD-1-11);Yang;J Thorac Oncol,2020
5. Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 Study;Yang;J Thorac Oncol,2021